Table 2.
Biological activities of fungal naturally occurring in bergamotane sesquiterpenoids.
| Compound Name | Biological Activity | Assay, Organism, or Cell Line | Biological Results | Ref. | |
|---|---|---|---|---|---|
| Compound | Positive Control | ||||
| E-β-trans-5,8,11-trihydroxybergamot-9-ene (4) | Cytotoxicity | MTT/U937 | 84.9 (IC50) | Doxorubicin 0.021 µM (IC50) | [29] |
| Craterodoratin M (7) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 15.43 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Craterodoratin N (8) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 13.26 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Craterodoratin O (9) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 17.12 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Craterodoratin Q (11) | Immunosuppressive | BALB/c mice T and B lymphocyte/Concanavalin A | 31.50 μM (IC50) | Cyclosporin A 0.04 μM (IC50) | [30] |
| Xylariterpenoid A (16) | Anti-inflammatory | Spectrophotometrically/LPS | 17.5 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| Xylariterpenoid B (17) | Anti-inflammatory | Spectrophotometrically/LPS | 21.0 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| Eutypeterpene B (18) | Anti-inflammatory | Spectrophotometrically/LPS | 13.4 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| Eutypeterpene C (19) | Anti-inflammatory | Spectrophotometrically/LPS | 16.8 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| Eutypeterpene D (20) | Anti-inflammatory | Spectrophotometrically/LPS | 21.4 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| Eutypeterpene E (21) | Anti-inflammatory | Spectrophotometrically/LPS | 18.7 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| Eutypeterpene F (22) | Anti-inflammatory | Spectrophotometrically/LPS | 24.3 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| (10S)-Xylariterpenoid A (23) | Anti-inflammatory | Spectrophotometrically/LPS | 86.0 μM (IC50) | Aminoguanidine 23.0 μM (IC50) | [34] |
| (10R)-Xylariterpenoid B (24) | Anti-inflammatory | Spectrophotometrically/LPS | 230.0 μM (IC50) | Aminoguanidine 23.0 μM (IC50) | [34] |
| Xylariterpenoid E (25) | Anti-inflammatory | Spectrophotometrically/LPS | 120.0 μM (IC50) | Aminoguanidine 23.0 μM (IC50) | [34] |
| Xylariterpenoid F (26) | Anti-inflammatory | Spectrophotometrically/LPS | 85.0 μM (IC50) | Aminoguanidine 23.0 μM (IC50) | [34] |
| Xylariterpenoid G (27) | Anti-inflammatory | Spectrophotometrically/LPS | 85.0 μM (IC50) | Aminoguanidine 23.0 μM (IC50) | [34] |
| Eutypeterpene A (28) | Anti-inflammatory | Spectrophotometrically/LPS | 21.0 μM (IC50) | Quercetin 17.0 μM (IC50) NG-monomethyl-L-arginine 9.7 μM (IC50) |
[35] |
| Craterodoratin C (30) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 12.62 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Craterodoratin S (42) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 22.68 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Craterodoratin J (54) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 19.40 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Craterodoratin L (56) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 13.71 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Massarinolin B (61) | Immunosuppressive | BALB/c mice T and B lymphocyte/Concanavalin A | 0.98 μM (IC50) | Cyclosporin A 0.04 μM (IC50) | [30] |
| Brasilterpene A (66) | Hypoglycemic | Spectrophotometrically/Diabetic zebrafish model | 449.3 pmol/larva (IC50) | Rosiglitazone 395.6 pmol/larva (IC50) | [45] |
| Brasilterpene C (68) | Hypoglycemic | Spectrophotometrically/Diabetic zebrafish model | 420.4 pmol/larva (IC50) | Rosiglitazone 395.6 pmol/larva (IC50) | [45] |
| Expansolide C (73) | α-Glucosidase inhibition | Spectrophotometrically/α-glucosidase enzyme | 0.50 mM (IC50) | Acarbose 1.90 mM (IC50) | [46] |
| Expansolide D (81) | α-Glucosidase inhibition | Spectrophotometrically/α-glucosidase enzyme | 0.50 mM (IC50) | acarbose 1.90 mM (IC50) | [46] |
| Purpurolide B (83) | Pancreatic lipase inhibition | Spectrophotometrically/pancreatic lipase enzyme | 5.45 μM (IC50) | Kaempferol 1.50 μM (IC50) | [47] |
| Purpurolide C (84) | Pancreatic lipase inhibition | Spectrophotometrically/pancreatic lipase enzyme | 6.63 μM (IC50) | Kaempferol 1.50 μM (IC50) | [47] |
| Purpurolide D (85) | Pancreatic lipase inhibition | Spectrophotometrically/pancreatic lipase enzyme | 1.22 μM (IC50) | Kaempferol 1.50 μM (IC50) | [48] |
| Purpurolide E (86) | Pancreatic lipase inhibition | Spectrophotometrically/pancreatic lipase enzyme | 6.50 μM (IC50) | Kaempferol 1.50 μM (IC50) | [48] |
| Purpurolide F (87) | Pancreatic lipase inhibition | Spectrophotometrically/pancreatic lipase enzyme | 7.88 μM (IC50) | Kaempferol 1.50 μM (IC50) | [48] |
| Donacinoic acid A (88) | Immunosuppressive | BALB/c mice T and B lymphocyte/LPS | 13.23 μM (IC50) | Cyclosporin A 0.47 μM (IC50) | [30] |
| Eutypellacytosporin A (94) | Cytotoxicity | CCK-8/DU145 | 17.1 μM (IC50) | Cisplatin 2.9 μM (IC50) | [52] |
| CCK-8/SW1990 | 7.3 μM (IC50) | Cisplatin 1.2 μM (IC50) | [52] | ||
| CCK-8/Huh7 | 8.4 μM (IC50) | Cisplatin 2.2 μM (IC50) | [52] | ||
| CCK-8/PANC-1 | 9.7 μM (IC50) | Cisplatin 4.5 μM (IC50) | [52] | ||
| Eutypellacytosporin B (95) | Cytotoxicity | CCK-8/DU145 | 11.0 μM (IC50) | Cisplatin 2.9 μM (IC50) | [52] |
| CCK-8/SW1990 | 4.9 μM (IC50) | Cisplatin 1.2 μM (IC50) | [52] | ||
| CCK-8/Huh7 | 4.9 μM (IC50) | Cisplatin 2.2 μM (IC50) | [52] | ||
| CCK-8/PANC-1 | 7.9 μM (IC50) | Cisplatin 4.5 μM (IC50) | [52] | ||
| Eutypellacytosporin C (96) | Cytotoxicity | CCK-8/DU145 | 13.5 μM (IC50) | Cisplatin 2.9 μM (IC50) | [52] |
| CCK-8/SW1990 | 9.6 μM (IC50) | Cisplatin 1.2 μM (IC50) | [52] | ||
| CCK-8/Huh7 | 11.2 μM (IC50) | Cisplatin 2.2 μM (IC50) | [52] | ||
| CCK-8/PANC-1 | 10.2 μM (IC50) | Cisplatin 4.5 μM (IC50) | [52] | ||
| Eutypellacytosporin D (97) | Cytotoxicity | CCK-8/DU145 | 13.4 μM (IC50) | Cisplatin 2.9 μM (IC50) | [52] |
| CCK-8/SW1990 | 8.2 μM (IC50) | Cisplatin 1.2 μM (IC50) | [52] | ||
| CCK-8/Huh7 | 9.6 μM (IC50) | Cisplatin 2.2 μM (IC50) | [52] | ||
| CCK-8/PANC-1 | 7.5 μM (IC50) | Cisplatin 4.5 μM (IC50) | [52] | ||